Telotristat ethyl is a Small Molecule owned by TerSera Therapeutics, and is involved in 24 clinical trials, of which 20 were completed, and 4 are ongoing.

LX-1032 acts by inhibiting tryptophan hydroxylase (TPH). Tryptophan hydroxylase (TPH) is the key regulator in serotonin (5-HT) biosynthesis that stimulates the release of GnRH and gonadotropins by acting at the level of hypothalamo-hypophyseal axis. In brain, 5-HT is expressed predominantly in preoptic area-hypothalamus (POA-HYP) region in teleosts. Excessive levels of serotonin have been implicated in symptoms associated with carcinoid syndrome.

The revenue for Telotristat ethyl is expected to reach a total of $367m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Telotristat ethyl NPV Report.

Telotristat ethyl was originated by Lexicon Pharmaceuticals and is currently owned by TerSera Therapeutics. Ipsen is the other company associated in development or marketing of Telotristat ethyl.

Telotristat ethyl Overview

Telotristat ethyl (LX1606, LX1032, Xermelo) is a paraneoplastic agent. It is formulated as tablets and film coated tablets for oral route of administration. Xermelo in combination with somatostatin analog (SSA) therapy indicated for the treatment of carcinoid syndrome diarrhea in adults that SSA therapy alone has inadequately controlled.

Telotristat ethyl (LX1606, LX1032) is under development for the treatment of neuroendocrine tumors, metastatic biliary tract cancer (intra-hepatic, extrahepatic and gallbladder). The drug candidate was also under development for pulmonary hypertension and ulcerative colitis.

Ipsen Overview

Ipsen is a global specialty biopharmaceutical company engaged in the manufacturing and distribution of drugs for the treatment of cancer, rare diseases and neurological diseases, including specialty pharmaceutical products. The company develops and commercializes novel medicines for cancer, neuroscience and rare diseases and also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatic diseases. Ipsen sells its drugs through a network of distributors and directly to hospitals in a few countries. The company operates its research and development facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.

The company reported revenues of (Euro) EUR2,999.1 million for the fiscal year ended December 2021 (FY2021), an increase of 11.6% over FY2020. In FY2021, the company’s operating margin was 28.4%, compared to an operating margin of 19.7% in FY2020. In FY2021, the company recorded a net margin of 21.6%, compared to a net margin of 20.4% in FY2020.

Quick View – Telotristat ethyl

Report Segments
  • Innovator (NME)
Drug Name
  • Telotristat ethyl
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.